What clinical trials might be relevant for Spindle Cell Sarcoma

Clinical Trials for Spindle Cell Sarcoma: What's Relevant for Marlo

Based on your documents and current NCCN guidelines, here are the clinical trial approaches most relevant to spindle cell sarcoma:

1. EGFR-Targeted Trials (Most Relevant to Marlo's Case)

Your treatment strategy document specifically mentions exploring afatinib (an irreversible pan-HER inhibitor) for EGFR ITD/KDD mutations. According to NCCN Soft Tissue Sarcoma Guidelines, targeted therapies based on specific molecular mutations are increasingly important for sarcoma management.

Questions to ask your oncology team:

• Are there any open clinical trials testing EGFR inhibitors specifically in pediatric sarcomas with EGFR mutations?
• What data supports afatinib over other EGFR inhibitors for this mutation profile?
• Are there basket trials (trials accepting multiple cancer types with the same mutation) that might include Marlo?

---

2. CAR-T Cell Therapy Trials

Your documents specifically mention St. Jude's 3CAR/B7-H3 CAR-T trial. According to NCCN guidelines, CAR-T approaches are being explored in sarcomas, though they work better in "hot" (immunologically active) tumors.

Important consideration from your strategy document: Your team noted that CAR-T may have limited efficacy in "cold" immune environments. This is why your document explores immune-priming strategies first (like the neoantigen vaccine approach).

Questions to ask:

• Is Marlo eligible for the St. Jude CAR-T trial?
• Should immune-priming (vaccine or checkpoint inhibitors) happen before CAR-T?
• What are the logistics and travel requirements?

---

3. Immunotherapy + Checkpoint Inhibitor Trials

According to NCCN guidelines, pembrolizumab and nivolumab have shown activity in soft tissue sarcomas, particularly in tumors with:

• High tumor mutational burden (TMB)
• Microsatellite instability (MSI-H)
• Mismatch repair deficiency (dMMR)

From your documents: Your team is pursuing immunopeptidomics analysis to develop a neoantigen-based vaccine, which could potentially be combined with checkpoint inhibitors.

Questions to ask:

• Has Marlo's tumor been tested for TMB, MSI status, or MMR deficiency?
• Are there trials combining neoantigen vaccines with anti-PD-1 checkpoint inhibitors?
• Which immunotherapy combinations might work best for a "cold" tumor?

---

4. Multikinase Inhibitor Trials

NCCN guidelines mention several multikinase inhibitors with activity in sarcomas:

• Pazopanib - antiangiogenic activity, used for advanced soft tissue sarcomas
• Sunitinib - tyrosine kinase inhibitor
• Regorafenib - shown benefit in doxorubicin-refractory soft tissue sarcomas (REGOSARC trial)
• Dasatinib - tested in rare sarcoma subtypes

Your strategy document explores MET inhibitor combinations (crizotinib, capmatinib, tepotinib) based on potential MET pathway crosstalk with EGFR.

Questions to ask:

• Does Marlo's tumor show MET amplification or overexpression?
• Are there trials testing EGFR + MET inhibitor combinations?
• What's the evidence for combination therapy vs. sequential therapy?

---

5. FAP-Targeted Radioligand Therapy Trials

Your strategy document specifically identifies this as a priority, noting that two German research groups have pediatric sarcoma experience with FAP (Fibroblast Activation Protein) radioligands.

From NCCN guidelines: While not yet standard of care, FAP-targeted approaches represent an emerging strategy for sarcomas with FAP expression in the tumor stroma.

Questions to ask:

• Which German centers have treated pediatric sarcomas with FAP radioligands?
• Is FAP-PET imaging available locally, or would travel be necessary?
• What are the eligibility criteria and safety data in pediatric patients?
• Can FAP therapy be combined with other treatments?

---

6. Antibody-Drug Conjugate (ADC) Trials

Your strategy document mentions screening against ~40 antibodies/ADCs through TRACER (Seattle Children's). NCCN guidelines note that ADCs targeting various antigens are being explored in sarcomas.

Questions to ask:

• Which ADCs show the most promise for spindle cell sarcomas?
• Are there open ADC trials that Marlo might be eligible for?
• How do ADC results from organoid screening inform trial selection?

---

7. Radiation + Systemic Therapy Combinations

Your strategy document explores carbon ion radiation therapy (CIRT) for radio-resistant tumors. Combined modality approaches are increasingly studied.

Questions to ask:

• Should radiation be combined with systemic therapy, or sequenced separately?
• Are there trials testing CIRT + targeted therapy combinations?
• What's the optimal timing relative to other treatments?

---

How to Find Trials: Practical Steps

1. Search ClinicalTrials.gov for:

   • "Spindle cell sarcoma" + "clinical trial"
   • "EGFR mutation" + "sarcoma"
   • "Pediatric sarcoma" + specific drug names
   • "Basket trials" for EGFR-mutant tumors

2. Contact major sarcoma centers:

   • St. Jude Children's Research Hospital (CAR-T trials)
   • MD Anderson Cancer Center
   • Memorial Sloan Kettering
   • Mayo Clinic (already consulting with you)

3. Leverage your team's connections:

   • Your documents show collaboration with multiple institutions
   • Ask about trials these centers are running or know about

4. Consider trial sequencing:

   • Your strategy document wisely notes: "Which decisions are time-sensitive vs. can wait for more data?"
   • Organoid drug screening results should inform trial selection

---

Key Questions for Your Oncology Team

Based on your comprehensive strategy document, prioritize these questions:

1. "Are there any EGFR ITD/KDD-specific trials or basket trials open right now?"
2. "Should we pursue immune-priming strategies (vaccine/checkpoint inhibitors) before CAR-T, given the 'cold' tumor biology?"
3. "Once organoid screening is complete, which drugs show the most promise for clinical trial matching?"
4. "What's the timeline for FAP imaging and potential radioligand therapy access?"
5. "Are there combination trials (EGFR inhibitor + MET inhibitor, or EGFR inhibitor + immunotherapy) that might be appropriate?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial eligibility and sequencing.